, , , , , , , , , , , , , , , , , ,

The newer Jynneos vaccine (MVA-BN) is supposed to be safer, than the earlier vaccines. It’s an “attenuated virus which is derived from Modified Vaccinia Ankara virus and which is characterized by the loss of its capability to reproductively replicate in human cell lines”, i.e. it is a “non-replicating smallpox vaccine”. https://patents.google.com/patent/US7923017B2/en Those who were vaccinated with the original vaccines are probably still immune. The question remains of why American children were force-vaccinated, with a dangerous vaccine, for a quarter of a century after the last US outbreak, which was also in NYC – far from much of the country. The dangers of the vaccine were known. https://miningawareness.wordpress.com/2022/05/23/immunity-from-smallpox-vaccine-persists-for-a-lifetime-97-of-the-time/

Ten years ago:
US to Stockpile Smallpox Vaccine – 2002-06-07

The U.S. federal government has just announced that, by the end of next year, it will stockpile enough smallpox vaccine to protect every U.S. citizen. Infectious disease expert Dr. Anthony Fauci was on hand at the New York Blood Center Thursday to discuss the implications of the plan. Dr. Fauci, the Director of the National Institute of Allergy and Infectious Diseases, agrees that having the vaccines on hand is wise. But, he says, the decision to use them cannot be made lightly.

First and foremost, he says, vaccinating people is risky. A small percentage of people, perhaps between 20 and 25 per million vaccinated, will die because they will cantract the diseases from vaccination. Furthermore, Dr. Fauci says, the panic generated by an outbreak of smallpox would likely wreak more havoc than the actual illness, as was the case with the anthrax cases late last year.

Bio-terrorism, he explained, should be looked at as part of a larger pattern of emerging and re-emerging diseases, and addressed accordingly. “I believe if we think of it in that context, we will have a sustainable capability for bio-defense and, in fact, the money that’s invested in bio-defense against bio-terrorism might ultimately be a boon for our public health system,” he said.

The knowledge that will come from trying to anticipate and prevent a biological attack, Dr. Fauci says, is “the good” that will come from the fear of bio-terrorism.

Nearly $1.8 billion of the $37.7 billion allotted to Homeland Security will go to addressing the threat of bio-terrorism. Dr. Fauci said the money will go into specific areas: research, increasing personnel, and the construction four new laboratories.https://www.voanews.com/a/a-13-a-2002-06-07-43-us-67274127/268193.html

$1.8 billion in 2002 is worth approximately $2.9 billion in 2022: https://www.bls.gov/data/inflation_calculator.htm

The newer Jynneos vaccine, which is supposed to be safer, than the earlier vaccine is an “attenuated virus which is derived from Modified Vaccinia Ankara virus and which is characterized by the loss of its capability to reproductively replicate in human cell lines”, i.e.it is a “non-replicating smallpox vaccine”.

Excerpt from News Release from Bavarian Nordic: “Since 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. To date, the Company has supplied nearly 30 million doses of the liquid-frozen version to HHS, with the vast majority being delivered for emergency use before approval of the vaccine by the FDA in 2019. Since 2009, BARDA has supported the development of a freeze-dried version of the vaccine with longer shelf-life to replace the stockpile and in 2017 awarded the Company a ten-year contract valued at USD 539 million for supply of freeze-dried vaccines. Part of this contract (USD 37 million) has funded the Phase 3 study. Also, under this contract Bavarian Nordic has produced bulk vaccine worth of USD 253 million which will add to the existing stock of bulk manufactured under previous orders, collectively resulting in approximately 13 million doses for future delivery. The majority of the contract (USD 299 million), however, will be realized upon supply of the freeze-dried doses, which will be manufactured at the Company’s the new fill-finish facility. https://web.archive.org/web/20220518053540/https://www.bavarian-nordic.com/investor/news/news.aspx?news=6569

MVA-BN is modified vaccinia Ankara virus-Bavarian Nordic.
Jynneos/MVA-BN: United States Patent (10) Patent No.: US 7.923,017 B2 Chaplin et al. (45) Date of Patent: *Apr. 12, 2011
The present invention provides an attenuated virus which is derived from Modified Vaccinia Ankara virus and which is characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus or its recombinants as a medicament or vaccine. Additionally, a method is provided for inducing an immune response even in immune-compromised patients, patients with pre-existing immunity to the vaccine virus, or patients undergoing antivi ral therapy.https://patents.google.com/patent/US7923017B2/en
jynneos https://www.fda.gov/media/131078/download
acam 2000 https://www.fda.gov/media/75792/download

See too (Go to original for embedded links): https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda
* May 18, 2022: FDA approved an intravenous (IV) formulation (PDF, 565 KB) of TPOXX (tecovirimat) to treat smallpox. The oral formulation of the drug was originally approved in 2018. The IV formulation is an option for those who are unable to swallow the oral capsule. Also see Therapeutics below
* June 4, 2021: FDA approves drug to treat smallpox – FDA approved Tembexa (brincidofovir) to treat smallpox. Although the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that
the virus that causes smallpox, the variola virus, could be used as a bioweapon. 
* November 15, 2019: FDA In Brief: FDA issues final guidance for development of smallpox treatments as part of critical preparedness efforts – FDA issued final guidance, Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention (PDF, 127 KB), which is designed to assist drug manufacturers designing studies to appropriately establish the safety and efficacy of drugs to treat or prevent smallpox infection. Also see Guidance for industry below
* September 24, 2019: FDA announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease. Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.
Fast Facts
* Variola virus is the causative agent of smallpox. 
* Smallpox was declared eradicatedExternal Link Disclaimer
 in 1980 by the World Health Organization, with no known cases of naturally occurring smallpox having occurred since 1977. The last outbreak of smallpox in the United States occurred in 1949.
* While there is no known immediate, direct threat of a biological attack using smallpox (i.e., an intentional release of Variola virus), concerns over the possible use of Variola virus in a biological attack have led to increased preparedness efforts.
* Transmission:Smallpox can be transmitted person-to-person via inhalation of virus-containing airborne droplets of saliva from an infected person. Transmission can also occur via contact with material from the smallpox pustules or crusted scabs, or through materials such as bedding or clothing that has been in contact with the pustules or scabs.
* Prevention: Smallpox can be prevented by vaccination with smallpox vaccine. The vaccine does not contain the smallpox virus and cannot give you smallpox. Also see Vaccines below
* Treatment: Treatment of patients with smallpox generally involves supportive care. TPOXX (tecovirimat) and Tembexa (brincidofovir) are approved for the treatment of smallpox. Also see Therapeutics below” https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda

Immunity from Smallpox Vaccine Persists for a Lifetime (97% of the time)